Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP0892 in adults with peanut allergy
NCT02851277Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Dec 2016
- Primary completion
- Dec 2018
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ASP0892 in peanut allergy (5 arms), sponsored by Astellas Pharma. Primary endpoints: Treatment-Emergent Adverse Events, Body temperature and 7 more. Started Dec 2016; status: completed.
02
Drugs
ASP0892
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT02851277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02851277.